Drug Discovery Outsourcing Market Surges to a US$7.52 Billion Valuation with Steady 7.2% CAGR from 2023 to 2033

The Drug Discovery Outsourcing Market demand is expected to grow at a stable CAGR of 7.2% between 2023 and 2033. The market is expected to surpass a market share of US$ 7.52 billion by 2033, from a value of US$ 3.75 billion in 2023.

  • The pharmaceutical industry’s expansion, as well as the increased penetration of digital technology and AI integration, are reshaping the market. Furthermore, the R&D process and the rise of drug discovery vendors in rising economies such as China and India drive market growth.
  • 80% of research on small and large medicinal compounds is outsourced to pharmaceutical behemoths. This is due to lower prices, more straightforward process, a larger workforce, and improved quality.
  • The market dynamics are also being shaped by the altered pharma business, which includes synergistic medications and sophisticated anti-infection drugs. Virus outbreaks like as Ebola and Coronavirus are also expanding the market’s user base.
  • Government policies integrate their medical policies, allowing pharma giants to collaborate and build the advanced drug discovery space. Thus, the demand for outsourced drug delivery services is in high demand.
  • The surge in respiratory patients with issues like tuberculosis, bronchitis, etc., also consumes a big chunk of the market. These conditions have increased lately as the post-corona impacts.

Experience the Magic of Learning through PDF Samples. @
https://www.futuremarketinsights.com/reports/sample/rep-gb-16937

Key Points

  • The United States market leads the Drug Discovery Outsourcing market in terms of market share in North America. The growth in the region is attributed to the expanding healthcare research budget, growing pharmaceutical companies, and strong bilateral business ties. The North American region held a substantial share of 35.5% in 2022.
  • The United Kingdom Drug Discovery Outsourcing market is another significant market from the European region. The market in the United Kingdom is owed by the technological integration and Ai-enabled drug discovery programs that promote cruelty-less procedures.
  • The Japan Drug Discovery Outsourcing market is anticipated to thrive at a healthy CAGR during the forecast period. Asia Pacific region leads the market in terms of CAGR. The Japanese market expands on the basis of increasing chronic diseases in the region and the higher geriatric population.
  • By workflow type, the lead identification & candidate optimization segment held 32.3% in 2022. This is due to the enhanced selectivity and fewer side effects.

Competitive Landscape

The key vendors work on delivering solutions that are easily flexible, affordable, and of high quality. Key competitors merge, acquire, and partner with other companies to increase their supply chain and distribution channel.

Key Players

  • Albany Molecular Research Inc.
  • EVOTEC
  • Laboratory Corporation of America Holdings
  • GenScript
  • Pharmaceutical Product Development, LLC
  • Charles River
  • WuXi AppTec
  • Merck & Co., Inc.
  • Thermo Fisher Scientific Inc.
  • Dalton Pharma Services
  • Oncodesign
  • Jubilant Biosys
  • DiscoverX Corp.
  • QIAGEN
  • Eurofins SE
  • Syngene International Limited
  • Dr. Reddy Laboratories Ltd.
  • Pharmaron Beijing Co., Ltd.
  • TCG Lifesciences Pvt Ltd.
  • Domainex Ltd.

Explore Comprehensive Report Here @
https://www.futuremarketinsights.com/reports/drug-discovery-outsourcing-market

Recent Market Developments

  • Syngene International Limited has added the SynVent integrated drug discovery option, a fully integrated therapeutic discovery and development process. It is likely to deliver a more effective and efficient target validation method.
  • Dr. Reddy Laboratories Ltd has signed a pact with EQRx, a biotechnology company, for the discovery, development, and commercialization.

Market Segmentation

Workflow Outlook:

  • Target Identification & Screening
  • Target Validation & Functional Informatics
  • Lead Identification & Candidate Optimization
  • Preclinical Development
  • Other Associated Workflow

Therapeutics Area Outlook:

  • Respiratory system
  • Pain and Anesthesia
  • Oncology
  • Ophthalmology
  • Hematology
  • Cardiovascular
  • Endocrine
  • Gastrointestinal
  • Immunomodulation
  • Anti-infective
  • Central Nervous System
  • Dermatology
  • Genitourinary System

Drug Type Outlook:

  • Small Molecules
  • Large Molecules (Biopharmaceuticals)

Service Type Outlook:

  • Chemistry Services
  • Biology Services

End-user Outlook:

  • Pharmaceutical & Biotechnology companies
  • Academic Institutes
  • Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogsYouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these